Vistagen Therapeutics, Inc. — Form 10-Q Summary
Reporting period: Quarter ended June 30, 2023 (the first quarter of fiscal 2024). Vistagen is a clinical-stage biopharmaceutical company with no approved products or product-sales revenue. Its pipeline includes five investigational pherine nasal sprays and oral candidate AV-101.
Financial performance and position
| Metric | Three months ended June 30, 2023 | Prior-year period |
|---|---|---|
| Revenue | $177,600 | $310,100 |
| Research and development expense | $4.20 million | $15.29 million |
| General and administrative expense | $2.98 million | $4.79 million |
| Operating loss | $7.00 million | $19.77 million |
| Net loss | $6.90 million | $19.78 million |
| Net loss per share, basic and diluted | $0.94 | $2.87 |
| Cash used in operating activities | $7.89 million | $15.97 million |
- Revenue was sublicense revenue under the AffaMed fasedienol agreement. No product-sales revenue was reported. Gross profit and operating margins are not separately reported; with revenue limited to sublicense income, standard product-margin comparisons are not meaningful.
- Cash and cash equivalents were $9.62 million at June 30, down from $16.64 million at March 31. Current assets were $11.58 million and current liabilities were $4.05 million. Stockholders’ equity was $6.85 million.
- Total liabilities were $8.18 million, including a $784,200 current insurance-premium financing note and operating lease liabilities of $2.49 million. The filing reports no off-balance-sheet arrangements.
- The company sold 561,418 shares through its at-the-market (ATM) facility during the quarter, receiving about $1.12 million net. After quarter-end, through the report’s issuance, it sold another 1,487,293 shares for $16.89 million gross at a weighted-average price of $11.36.
Changes versus the prior comparable period
- Revenue declined by about 43%. Operating expenses fell by about 64%, with R&D down about $11.1 million and G&A down about $1.8 million; the net loss narrowed by about 65%.
- Management attributed lower R&D costs mainly to completion, pausing, or termination of fasedienol studies and reduced related development activity. Lower G&A primarily reflected reduced pre-launch marketing, lower stock-based compensation, and fewer investor and public-relations initiatives.
- Operating cash use improved by about $8.1 million year over year, but remained substantial. The company reported no investing cash outflow in the quarter.
- A one-for-30 reverse stock split took effect June 6, 2023; share and per-share figures in the filing are retrospectively adjusted. Shares issued increased from 7.32 million at March 31 to 7.88 million at June 30, principally reflecting ATM sales.
Outlook, developments, and risks
- Going concern and funding: Vistagen said its $9.6 million of quarter-end cash would not fund planned operations for the 12 months following issuance of the financial statements, raising substantial doubt about its ability to continue as a going concern. The subsequent ATM proceeds provide additional cash, but the filing does not state that they resolve the going-concern uncertainty or provide a revised runway estimate. The company expects continued losses and plans to seek additional equity, debt, grants, or strategic collaborations; availability and terms are uncertain.
- Planned development, subject to adequate funding or partners: Prepare for Phase 3 PALISADE-3 and FEARLESS studies of fasedienol; pursue Phase 2B development of itruvone; advance IND-enabling work for PH80, PH15, and PH284; assess Phase 2A development of AV-101; and conduct nonclinical studies. The filing anticipated PALISADE-3 could begin in the first half of calendar 2024 and FEARLESS in the second half of 2024.
- Fasedienol: PALISADE-1 failed its primary efficacy endpoint in 2022. In early August 2023, after the quarter ended, Vistagen reported positive topline results from PALISADE-2, which was completed with 141 subjects rather than the originally planned 208. The primary SUDS endpoint favored fasedienol over placebo (between-group difference −5.8; p=0.015); reported secondary and exploratory response measures also favored treatment. The company described tolerability as favorable. These results are topline and do not establish regulatory approval.
- Other pipeline updates: The company completed a small Phase 1 study of itruvone in June 2023, reporting no treatment-related serious adverse events or discontinuations due to adverse events. It also described positive results from a previously unpublished exploratory Phase 2A study of PH80 for menopausal hot flashes and said it was preparing a U.S. IND submission.
- AffaMed agreement: The agreement covers fasedienol in specified Asian territories and includes up to $172 million in potential development and commercial milestones plus royalties. At June 30, $2.85 million remained deferred revenue. The company estimated its remaining performance obligation would be completed around mid-2027; future milestone and royalty receipts are not assured.
- Key risks: Clinical failures or delays, dependence on external contract research and manufacturing organizations, regulatory and commercialization uncertainty, competition, intellectual-property challenges, possible dilution from future financing, and Nasdaq listing requirements. The company also cited potential COVID-19-related olfactory dysfunction as a risk to pherine activity and clinical results.
- Management stated disclosure controls and procedures were effective at quarter-end and reported no material change in internal control over financial reporting during the quarter. The filing reported no legal proceedings.
Important facts for investors to verify
- Cash available after the post-quarter ATM sales, cash burn, and the company’s updated operating runway and going-concern assessment.
- Final PALISADE-2 data, study design and regulatory implications, and whether PALISADE-3 and FEARLESS begin on the stated timelines.
- Funding required to advance the broader pipeline, availability of strategic partners, and the extent of future equity dilution.
- Progress on the itruvone Phase 2B plan, PH80 IND submission, and development paths for PH15, PH284, and AV-101.
- Changes to the estimated timing of AffaMed-related revenue recognition and the prospects for milestones or royalties.